I-SPY 2 Graduates First Two Drugs for Breast Cancer

Dec 27, 2013

|

NEW YORK (GenomeWeb News) – The Foundation for the National Institutes of Health on Thursday announced that the I-SPY 2 Trial has graduated the first two drugs from its multidrug standing platform trial.

The two drugs are veliparib, developed by AbbVie, and neratinib, developed by Puma Biotechnology. Both are for breast cancer.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

More Common Than Thought

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

Even for Prizes, Women Get Less Money

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

This Week in Nature

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Scramble to Keep the Work Alive

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.

Featured White Papers

How to Use CrownBio's Integrated Oncology Portfolio for Target Identification and Mechanism of Action Elucidation

Immuno-Oncology: 3 Strategies for Applying Humanized Models

A Guide to Selecting Your Next Immuno-Oncology Model

InnoStamp 40 and InnoScan 1100AL: a complete automated platform for microstructured cell arrays

Jan

30

Featured Webinar

A Long-Read vs. Short-Read Platform Comparison: Best NGS Approaches for Microbiome Studies

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Feb

21

Featured Webinar

Case Study: 'Companion Informatics' to Automate Immunotherapy Manufacturing and Treatment

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Feb

26

Featured Webinar

A Cellular and Molecular Phenotyping Pipeline for Target Characterization in FFPE Biobank Samples

This webinar will demonstrate how a research team at the Firestone Institute for Respiratory Health at McMaster University developed a cellular and molecular phenotyping pipeline using archived samples of lung tissue derived from patients diagnosed with fibrotic interstitial lung disease.

Main menu